When was Codiak BioSciences founded?

Codiak BioSciences was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Codiak BioSciences located?

Codiak BioSciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Codiak BioSciences have?

As of Dec 31, 2022, Codiak BioSciences has 48 employees, reflecting a 52% year-over-year decline in headcount.

Is Codiak BioSciences a funded company?

Codiak BioSciences is a funded company, having raised a total of $168M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 25, 2015.

When was the latest funding round of Codiak BioSciences?

Codiak BioSciences' latest funding was a $***** Series C round on Nov 29, 2017, with participation from 10 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $453M in funding in 2026 to date.

What is the annual revenue of Codiak BioSciences?

Annual revenue of Codiak BioSciences is $22.9M as on Dec 31, 2021.

Where does Codiak BioSciences rank among its competitors?

Codiak BioSciences ranks 393rd amongst 2556 active competitors, of which 881 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Codiak BioSciences?

Codiak BioSciences' top competitors include Jazz Pharmaceuticals, Guardant Health and Sana Biotechnology. Among them, Guardant Health secured the most recent funding round in November, 2025.

Codiak BioSciences - 2026 Company Profile, Funding, Competitors & Financials

Codiak BioSciences is a public company based in Cambridge (United States), founded in 2015. It operates as a Developer of exosome-based drugs and diagnostics for cancer treatment. Codiak BioSciences has raised $168M in funding from Arch Venture Partners and Flagship Pioneering. The company has 2556 active competitors, including 881 funded and 633 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Guardant Health and Sana Biotechnology.

Company Details

Developer of exosome-based drugs and diagnostics for cancer. The company has developed natural vesicles that mediate intercellular communication which is used for therapeutics and diagnostic solutions. The company has developed exoSTING solid tumors for treating cancer diseases. The company's other products include exoIL-12 for melanoma, exoASO-STAT3 used to treat hematologic and hepatic cancers.

Website: codiakbio.com
Social
Email ID: *****@codiakbio.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Public

Total Funding

$168M in 3 rounds

Latest Funding Round

Series C, Nov 29, 2017, $*****

Investors

Arch Venture Partners & 11 more

Ranked

393^rd among 2556 active competitors

Annual Revenue

$22.9M as on Dec 31, 2021

Employee Count

48 as on Dec 31, 2022

Similar Companies

Pacific Edge & 70 more

Exit Details

Public

View Codiak BioSciences' full profile

Codiak BioSciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Codiak Biosciences, Inc. CIN: 474926530 , United States, Active		$22.9M (As on Dec 31, 2021)	48 (As on Dec 31, 2022)	-

Codiak BioSciences got listed on Oct 14, 2020.

Click here to take a look at Codiak BioSciences's IPO in detail

Codiak BioSciences has raised a total funding of $168M over 3 rounds. Its first funding round was on Nov 25, 2015. Its latest funding round was a Series C round on Nov 29, 2017 for $*****. 10 investors participated in its latest round. Codiak BioSciences has 12 institutional investors.

Here is the list of recent funding rounds of Codiak BioSciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 29, 2017	3991194	Series C	1803820	4432054	3421474	1932978
Jan 26, 2016	7028799	Series B	7181723	5382027	3675283	Alexandria & 1 more
Nov 25, 2015	2514138	Series A	6252542	4638375	Arch Venture Partners & 1 more	Fidelity Investments & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Codiak BioSciences's funding rounds and investors

Codiak BioSciences' employee count trend

Codiak BioSciences has 48 employees as of Dec 22. The total employee count is 53.0% lower than what it was in Dec 21. Here is Codiak BioSciences's employee count trend over the years:

Employee count trend for Codiak BioSciences

Uncover Codiak BioSciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Codiak BioSciences include Jazz Pharmaceuticals, Guardant Health and Sana Biotechnology. Here is the list of Top 10 competitors of Codiak BioSciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Sequoia Capital & 24 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
393rd	Codiak BioSciences 2015, Cambridge (United States), Public	Developer of exosome-based drugs and diagnostics for cancer treatment	$168M	Boxer Capital, Fidelity Investments & 10 others	53/100